- ￥5225
- OriGene
- 美国
- SM1009F
- 2026年04月01日
- FC
- Mouse
- Human
企业认证
相关产品推荐更多 >
Pdpn hamster monoclonal antibody, clone 811, Purified
￥4752SIGLEC5 / SIGLEC14 mouse monoclonal antibody, clone 1A5, PE, Purified
￥6369
SNAP25 mouse monoclonal antibody, clone OTI4B2 (formerly 4B2), HRP conjugated
￥3990
Rabbit Polyclonal Anti-OR1A2 Antibody
￥5250
ING2 mouse monoclonal antibody,clone 3B11, HRP conjugated
￥3990
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Purified human IgG. Spleen cells from immunised BALB/c mice were fused with cells of the mouse NSI myeloma cell line.
- 形态：
PBS, pH7.4 containing 0.09% Sodium Azide and 1% Bovine Serum AlbuminLabel: FITCState: Liquid purified IgG fraction.Label: Fluorescein Isothiocyanate Isomer 1
- 保存条件：
Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.Avoid repeated freezing and thawing.This product is photosensitive and should be protected from light.
- 克隆性：
Monoclonal
- 适应物种：
Human
- 保质期：
Stable for 12 months from date of receipt.
- 目录编号：
SM1009F
- 级别：
科研级
- 库存：
4周
- 供应商：
OriGene
- 宿主：
Mouse
- 应用范围：
FC
- 抗体英文名：
Human Lambda Light Chain mouse monoclonal antibody, clone Mc24-IC6, FITC
- 抗体名：
Human Lambda Light Chain mouse monoclonal antibody, clone Mc24-IC6, FITC
- 规格：
100 ug
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Rapid Isotyping of Mouse Monoclonal Antibodies
Determination of class and subclass of monoclonal antibodies (MAbs) is important because several immunochemical and functional properties of antibodies depend on the isotype. Knowledge of the light-chain isotype (κ for 95% or λ
Monoclonal Antibody Lead Characterization: In Vitro and In Vivo Methods
This chapter describes in vitro and in vivo methods to characterize a lead monoclonal antibody candidate in the drug discovery setting. Approaches to characterize monoclonal antibody specificity, heavy and light chain composition
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
